Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Vurdering av immunfunksjon ved sepsis

21. september 2026 oppdatert av: University of Minnesota

Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Observasjonsmessig

Registrering (Antatt)

150

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Mrunmayi Tilak
  • Telefonnummer: 612-624-9990
  • E-post: mtilak@umn.edu

Studiesteder

    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with and without sepsis in the ICU, compared to healthy volunteers

Beskrivelse

ICU With Sepsis Inclusion Criteria:

  • Age ≥ 18

  • Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"

  • Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:

    1. Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
    2. An alteration in mental status
    3. Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
    1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)

ICU Without Sepsis Inclusion Criteria:

  • Age ≥ 18
  • Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis

Healthy Volunteer Inclusion Criteria

  • Age greater or equal to 18
  • ASA status 1, 2 or 3
  • May include patients who are receiving dialysis in an outpatient setting

Exclusion Criteria (all groups):

  • Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
  • Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
  • Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
  • Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
  • Patients with active or a history of acute or chronic lymphocytic leukemia
  • Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
  • Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
  • Participation in another investigational interventional drug study within the past 4 weeks
  • Current pregnancy
  • Current incarceration

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Friske Frivillige

No intervention is included in this study

ICU -pasienter med sepsis

No intervention is included in this study

ICU -pasienter uten sepsis

No intervention is included in this study

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
EliSpot - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
EliSpot - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
EliSpot - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
EliSpot - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
EliSpot - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
EliSpot - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Ex Vivo TNF Production - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Ex Vivo TNF Production - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Ex Vivo TNF Production - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Ex Vivo TNF Production - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Ex Vivo TNF Production - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Ex Vivo TNF Production - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Cytokines in Serum - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Cytokines in Serum - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Cytokines in Serum - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Cytokines in Serum - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Cytokines in Serum - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Cytokines in Serum - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Quantification of Chemokines in Serum - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Quantification of Chemokines in Serum - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Quantification of Chemokines in Serum - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Quantification of Chemokines in Serum - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Quantification of Chemokines in Serum - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Quantification of Chemokines in Serum - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
Transcriptional Profiling - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
Transcriptional Profiling - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
Transcriptional Profiling - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
Transcriptional Profiling - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
Transcriptional Profiling - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
Transcriptional Profiling - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28
CBC - Day 1
Tidsramme: Day 1

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 1
CBC - Day 4
Tidsramme: Day 4

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 4
CBC - Day 7
Tidsramme: Day 7

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 7
CBC - Day 14
Tidsramme: Day 14

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 14
CBC - Day 21
Tidsramme: Day 21

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 21
CBC - Day 28
Tidsramme: Day 28

Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes

Day 28

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Thomas Griffith, PhD, University of Minnesota

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mars 2026

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. november 2028

Datoer for studieregistrering

Først innsendt

26. august 2025

Først innsendt som oppfylte QC-kriteriene

26. august 2025

Først lagt ut (Faktiske)

4. september 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere